← Back to all signals
BMY · Q2 2026

BRISTOL MYERS SQUIBB CO

Reported 2026-07-30
BEAT
51EarnIQ signal
↗

Confidence rising

Mild quarter-over-quarter shift

Strong growth portfolio momentum and raised full-year guidance underscore robust execution and expanding market share.

  • ✓Guidance was raised, with high specificity.
  • ✓Management tone registered as confident (85/100).
  • ✓EarnIQ detected 0 potential management deflections.
Headline–confidence gap

Headline confirmed

Management confidence reinforces the reported beat.

EPS: reported vs expected+27.2%$2.04 vs $1.60
Revenue: reported vs expected+9.4%$13.0B vs $11.9B
Guidance specificityHighRaised
Market expectations supplied by Finnhub · Reported vs consensus estimate

The Growth Portfolio continues to deliver, achieving 15% growth in the quarter, and represents an expanding share of our overall business.

Premium intelligence

The evidence behind the signal

Full report
Management language

Why confidence moved

“The Growth Portfolio continues to deliver, achieving 15% growth in the quarter, and represents an expanding share of our overall business”
“We are building from a position of strength and progressing a differentiated pipeline designed to generate long-term value.”
“As a result of our consistent execution and continued momentum, we are raising our 2026 full-year outlook.”
Guidance specificity
90/100

High specificity

Raised full-year 2026 revenue guidance to ~$49.0 - $50.0 billion and increased non-GAAP EPS range to $6.75 - $7.00.

Pressure point
!

Expected continued generic impacts across

0 potential deflections detected in management communication.

Narrative break

What changed

Expansion of collaboration with NVIDIA to deploy Vera Rubin NVL72 AI infrastructure and strategic agreement with Anthropic to deploy Claude.

Q&A evidence

Management responses

No material Q&A deflections were detected.

Key positives
  • Growth Portfolio revenues increased 15% to $7.6 billion, led by Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, and Opdualag.
  • Raised full-year 2026 revenue guidance to a range of ~$49.0 billion to $50.0 billion.
  • Significant pipeline progress with multiple regulatory acceptances and approvals including Reblozyl and mezigdomide.
Key risks
  • Expected continued generic impacts across the remainder of the Legacy Portfolio.
  • Increased operating expenses driven by investments in key pipeline programs and new product launches.
  • Foreign exchange volatility affecting reported international revenues.
Topic velocity

Language versus prior quarter

M&ANew
CostNew
ChinaNew
MarginNew
RecordNew
iPhoneNew
Signal composition

What drove the EarnIQ score

Tone+20
Eps Beat+0
Guidance+15
New Signal+8
Miss Penalty+0
Qoq Improvement+8
Deflection Penalty+0